The consultancy is expected to commence on 1 January 2014, subject to negotiation of contract terms. The contract will cover public affairs monitoring as well as providing policy, public affairs and communications support to the in-house team.
Commenting on the appointment, Catherine Meaden, ABPI Communications Director, said:
“The standard of proposals we received for this contract were extremely high, but Weber Shandwick stood out by presenting a compelling campaigning approach as well as having a good understanding of the ABPI’s priorities. We are very much looking forward to working with them on proactive engagement with our stakeholders on significant issues and to showcase the valuable contribution industry makes.”
Weber Shandwick’s Head of Healthcare Public Affairs Tamora Langley, who will lead the account, said:
“The ABPI has a fantastic story to tell in 2014, and we are very excited to be working with them. The pharmaceutical industry is key to our country’s economic recovery, and growth remains the single most pressing issue ahead of the General Election. This pre-election period provides a unique opportunity for the ABPI to set the industry agenda and we look forward to helping support the objectives of the Association and its members. ”
Notes to Editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410
Mobile: +44 (0) 7808 641811 or +44 7850 312064